Cuspidi Cesare, Meani Stefano, Fusi Veronica, Severgnini Barbara, Valerio Cristiana, Catini Eleonora, Leonetti Gastone, Magrini Fabio, Zanchetti Alberto
Istituto di Medicina Cardiovascolare, Centro di Fisiologia e Ipertensione, Università degli Studi di Milano, Ospedale Maggiore Policlinico, IRCCS, Milan, Italy.
J Hypertens. 2004 Oct;22(10):1991-8. doi: 10.1097/00004872-200410000-00023.
The prevalence and the relationship between metabolic syndrome, and target organ damage (TOD) in essential hypertensive patients has not been fully explored to date.
To investigate the association between metabolic syndrome, as defined by the ATP III report, and cardiac and extracardiac TOD, as defined by the 2003 ESH-ESC guidelines for management of hypertension, in a large population of never-treated essential hypertensives.
A total of 447 grade 1 and 2 hypertensive patients (mean age 46 +/- 12 years) who were attending a hypertension hospital outpatient clinic for the first time underwent the following procedures: (i) physical examination and repeated clinic blood pressure measurements; (ii) routine examinations; (iii) 24-h urine collection for microalbuminuria; (iv) 24-h ambulatory blood pressure monitoring; (v) echocardiography; and (vi) carotid ultrasonography. Metabolic syndrome was defined as involving at least three of the following alterations: increased waist circumference, increased triglycerides, decreased high-density lipoprotein cholesterol, increased blood pressure, or high fasting glucose. Left ventricular hypertrophy (LVH) was defined according to two different criteria: (i) 125 g/m in men and 110 g/m in women; (ii) 51 g/h in men and 47 g/h in women.
The 135 patients with metabolic syndrome (group I) were similar for age, sex distribution, known duration of hypertension and average 24-h, daytime and night-time ambulatory blood pressure to the 312 patients without it (group II). The prevalence of altered left ventricular patterns (LVH and left ventricular concentric remodelling) was significantly higher in group I (criterion a = 30%, criterion b = 42%) than in group II (criterion a = 23%, criterion b = 30%, P < 0.05 and P < 0.01, respectively). A greater urinary albumin excretion (17 +/- 35 versus 11 +/- 23 mg/24 h, P = 0.04) was also found in group I compared to group II. There were no significant differences between the two groups in the prevalence of carotid intima-media thickening and plaques.
These results from a representative sample of untreated middle-aged hypertensives show that: (i) the metabolic syndrome is highly prevalent in this setting and (ii) despite similar ambulatory blood pressure values, patients with metabolic syndrome have a more pronounced cardiac and extracardiac involvement than those without it.
迄今为止,原发性高血压患者中代谢综合征与靶器官损害(TOD)之间的患病率及其关系尚未得到充分研究。
在大量未经治疗的原发性高血压患者中,研究ATP III报告定义的代谢综合征与2003年欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)高血压管理指南定义的心脏及心脏外TOD之间的关联。
共有447例1级和2级高血压患者(平均年龄46±12岁)首次前往高血压医院门诊就诊,接受了以下检查:(i)体格检查和重复测量诊室血压;(ii)常规检查;(iii)收集24小时尿液检测微量白蛋白尿;(iv)24小时动态血压监测;(v)超声心动图检查;(vi)颈动脉超声检查。代谢综合征定义为至少存在以下三种改变:腰围增加、甘油三酯升高、高密度脂蛋白胆固醇降低、血压升高或空腹血糖升高。左心室肥厚(LVH)根据两种不同标准定义:(i)男性≥125g/m²,女性≥110g/m²;(ii)男性≥51g/h,女性≥47g/h。
135例代谢综合征患者(I组)在年龄、性别分布、已知高血压病程以及平均24小时、日间和夜间动态血压方面与312例无代谢综合征患者(II组)相似。I组左心室形态改变(LVH和左心室向心性重构)的患病率显著高于II组(标准a:I组为30%,II组为23%,P<0.05;标准b:I组为42%,II组为30%,P<0.01)。与II组相比,I组尿白蛋白排泄量也更高(17±35 vs 11±23mg/24h,P = 0.04)。两组在颈动脉内膜中层增厚和斑块患病率方面无显著差异。
这些来自未经治疗的中年高血压患者代表性样本的结果表明:(i)在这种情况下代谢综合征非常普遍;(ii)尽管动态血压值相似,但代谢综合征患者比无代谢综合征患者的心脏和心脏外受累更为明显。